source
- Jazz partners with AbCellera on $4 billion deal to develop next-generation T-cell engagers for solid tumorsJazz Pharmaceuticals disclosed a collaboration with AbCellera aimed at creating next-generation T-cell-engaging antibodies for solid tumors. Under the agreement Jazz will pay $56 million up front…
- FDA signals openness to Moderna flu vaccine and clears UniQure's Huntington's therapy as Eli Lilly acquires 4E TherapeuticsThe U.S. Food and Drug Administration indicated it is receptive to Moderna's seasonal flu vaccine ahead of the upcoming advisory committee meeting, suggesting a smoother review path. UniQure repor…STAT · 2mo agoRegulatoryPositive